The Future of Drug Discovery

1st Edition

Who Decides Which Diseases to Treat?

Print ISBN: 9780124071803
eBook ISBN: 9780124095199
Imprint: Academic Press
Published Date: 29th May 2013
Page Count: 376
34.95 + applicable tax
27.99 + applicable tax
44.95 + applicable tax
Compatible Not compatible
VitalSource PC, Mac, iPhone & iPad Amazon Kindle eReader
ePub & PDF Apple & PC desktop. Mobile devices (Apple & Android) Amazon Kindle eReader
Mobi Amazon Kindle eReader Anything else

Institutional Access


The Future of Drug Discovery: Who decides which diseases to treat? provides a timely and detailed look at the efforts of the pharmaceutical industry and how they relate, or should relate, to societal needs. The authors posit that as a result of increasing risk aversion and accelerated savings in research and development, the industry is not developing drugs for increasingly prevalent diseases, such as Alzheimer’s disease, untreatable pain, antibiotics and more. This book carefully exposes the gap between the medicines and therapies we need and the current business path. By analyzing the situation and discussing prospects for the next decade, the The Future of Drug Discovery is a timely book for all those who care about the development needs for drugs for disease.

Key Features

  • Provides an in-depth, broad perspective on the crisis in drug industry
  • Exposes the disconnect between what society needs and what the drug companies are working on
  • Analyses and projects over 10 years into the future
  • Explains what it means for scientists and society
  • Determines what is needed to be done to make sure that the industry responds to society's needs, remains commercially attractive and answers the question as to who decides which diseases to treat


Biomedical researchers involved in drug discovery in industry and academic settings, physicians, patient advocacy groups, health economists and regulatory officials

Table of Contents

Expert Reviews for The Future of Drug Discovery: Who Decides Which Diseases to Treat?



Foreword by Graeme Bilbe PhD

Foreword by James H Eberwine PhD

Foreword by Eduard Enrico Holdener MD

Chapter 00: Introduction

What medicines you will need & why you might not ever have them

Aging is the major risk factor for disease

Painful truth & AD

More government action required

The decisiveness & divisiveness of market access

Government can change the future

Not all is doom & gloom

What can society do?

Chapter 01. Why there will be new drugs despite the ongoing “crisis” of drug development in Big Pharma

Pharmaceutical industry in crisis & consolidation

Why is there a strong belief that new future medicines will come?

Safe drugs in new indications: one does not always need new drugs for new therapies

Preventive drugs: large, long, expensive, convincing trials

Age as a risk factor & keeping costs in check

Newly orphaned diseases: more government needed

Chapter 02. The need for medicines grows

Small molecules & biologicals

The aging population

Rare or “orphan” diseases

Drug development: adding biologicals

Treatment of MS

Treatment of RA

Recombinant proteins as treatments

Future recombinant proteins as treatments

Pharma, governments, & nongovernmental organizations

Chapter 03. Medicines are becoming better: some of the breakthrough medicines of the past decades

Significant progress since WW II

The great beginning & the feared end of extremely profitable drug discovery

Drug discovery recovery, phase 1

Drug discovery arrested?

Meta-analysis matters: new twist on old information

New uses for safe drugs


No. of pages:
© Academic Press 2013
Academic Press
eBook ISBN:
Paperback ISBN:


"This book reviews in exquisite detail the drug development process from the initial inception of an idea through the life cycle of a new drug entity. The authors also spend an appropriate amount of time on the role of government-funded research programs along with the role of medium and small biotechnology companies in the drug treatment of diseases…Summing Up: Highly recommended." --CHOICE Reviews Online, December 2013

"Bartfai and Lees describe the looming crisis in health care…They target society in general as their audience, because of the need for the public to understand what is happening and why they should be concerned. The book is a compendium of data and analysis and there are many tables and figures supporting the text." --Reference and Research Book News, August 2013

"A remarkable compendium of hard data and wise prescription for the pharmaceutical industry." --Michael S. Brown, 1985 Novel Laureate in Medicine or Physiology, UT Southwestern Medical Center

"This is an extraordinary, insightful and provocative book that should be read by all those concerned by the progress of biomedicine, from scientists to politicians." --Jean-Pierre Changeux, Collège de France and l’Institut Pasteur

"Bartfai and Lees raise critical issues confronting the search for new medicines.  Their analysis is cogent, and their proposals thoughtful and thought provoking.  For anyone curious about where new medicines come from, and what it will take for the BioPharma industry to bring new treatments to patients with Alzheimer's disease, diabetes, depression, cancer, and more, this is a must read." --Michael D. Ehlers, Senior VP Pfizer and CSO Neuroscience, former Howard Hughes Investigator, Duke University

"This book is a must read for students, prescribing physicians, academic and industry researchers, analysts, patient groups, business and scien